Analysts Set Heron Therapeutics Inc (NASDAQ:HRTX) Price Target at $53.43

Heron Therapeutics Inc (NASDAQ:HRTX) has received an average recommendation of “Buy” from the twelve analysts that are currently covering the firm, MarketBeat reports. Two equities research analysts have rated the stock with a sell rating, two have assigned a hold rating and eight have given a buy rating to the company. The average twelve-month price target among brokers that have issued ratings on the stock in the last year is $53.43.

Several research firms have recently weighed in on HRTX. BidaskClub downgraded Heron Therapeutics from a “sell” rating to a “strong sell” rating in a report on Thursday, April 18th. Zacks Investment Research cut Heron Therapeutics from a “hold” rating to a “sell” rating in a research note on Thursday, May 9th. ValuEngine upgraded Heron Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday, May 22nd. Stifel Nicolaus restated a “buy” rating and set a $38.00 price target on shares of Heron Therapeutics in a research note on Wednesday, May 1st. Finally, Cantor Fitzgerald cut Heron Therapeutics from an “overweight” rating to a “neutral” rating in a research note on Monday, March 4th.

Shares of HRTX stock traded down $0.24 during trading hours on Tuesday, hitting $17.04. The stock had a trading volume of 438,947 shares, compared to its average volume of 1,057,223. The company has a market capitalization of $1.40 billion, a P/E ratio of -6.98 and a beta of 1.61. Heron Therapeutics has a twelve month low of $16.20 and a twelve month high of $42.90. The company has a current ratio of 4.40, a quick ratio of 4.06 and a debt-to-equity ratio of 0.04.

Heron Therapeutics (NASDAQ:HRTX) last posted its quarterly earnings data on Thursday, May 9th. The biotechnology company reported ($0.80) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.50) by ($0.30). The firm had revenue of $31.60 million during the quarter, compared to analyst estimates of $28.04 million. Heron Therapeutics had a negative net margin of 194.43% and a negative return on equity of 49.22%. Heron Therapeutics’s revenue was up 172.4% compared to the same quarter last year. During the same period in the previous year, the company posted ($1.09) earnings per share. Research analysts predict that Heron Therapeutics will post -2.66 EPS for the current fiscal year.

In related news, Director John Poyhonen purchased 3,000 shares of the business’s stock in a transaction dated Wednesday, May 22nd. The stock was acquired at an average price of $17.55 per share, for a total transaction of $52,650.00. Following the completion of the purchase, the director now directly owns 13,000 shares of the company’s stock, valued at $228,150. The purchase was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Waage Christian purchased 1,400 shares of the business’s stock in a transaction dated Wednesday, May 15th. The shares were bought at an average price of $18.04 per share, with a total value of $25,256.00. Following the purchase, the director now directly owns 1,400 shares of the company’s stock, valued at $25,256. The disclosure for this purchase can be found here. 12.56% of the stock is owned by corporate insiders.

A number of large investors have recently added to or reduced their stakes in HRTX. Advisor Group Inc. raised its position in Heron Therapeutics by 96.4% in the first quarter. Advisor Group Inc. now owns 1,416 shares of the biotechnology company’s stock worth $35,000 after acquiring an additional 695 shares in the last quarter. Parallel Advisors LLC raised its position in Heron Therapeutics by 247.4% in the first quarter. Parallel Advisors LLC now owns 1,685 shares of the biotechnology company’s stock worth $41,000 after acquiring an additional 1,200 shares in the last quarter. Pearl River Capital LLC raised its position in Heron Therapeutics by 1,900.0% in the first quarter. Pearl River Capital LLC now owns 2,000 shares of the biotechnology company’s stock worth $48,000 after acquiring an additional 1,900 shares in the last quarter. US Bancorp DE purchased a new position in Heron Therapeutics in the first quarter worth $57,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank raised its position in Heron Therapeutics by 24.3% in the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 4,747 shares of the biotechnology company’s stock worth $123,000 after acquiring an additional 929 shares in the last quarter.

Heron Therapeutics Company Profile

Heron Therapeutics, Inc, a biotechnology company, engages in developing treatments to address unmet medical needs. The company's product candidates utilize its proprietary Biochronomer drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.

Read More: Strangles

Analyst Recommendations for Heron Therapeutics (NASDAQ:HRTX)

Receive News & Ratings for Heron Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.